Cargando…

The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis

OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Administration of FGF19 to obese/diabetic mice lowers body weight, improves insulin sensitivity, and enhances glycemic control. The primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonellis, Patrick J., Droz, Brian A., Cosgrove, Richard, O'Farrell, Libbey S., Coskun, Tamer, Perfield, James W., Bauer, Steven, Wade, Mark, Chouinard, Tara E., Brozinick, Joseph T., Adams, Andrew C., Samms, Ricardo J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6807368/
https://www.ncbi.nlm.nih.gov/pubmed/31767164
http://dx.doi.org/10.1016/j.molmet.2019.09.006
_version_ 1783461705377906688
author Antonellis, Patrick J.
Droz, Brian A.
Cosgrove, Richard
O'Farrell, Libbey S.
Coskun, Tamer
Perfield, James W.
Bauer, Steven
Wade, Mark
Chouinard, Tara E.
Brozinick, Joseph T.
Adams, Andrew C.
Samms, Ricardo J.
author_facet Antonellis, Patrick J.
Droz, Brian A.
Cosgrove, Richard
O'Farrell, Libbey S.
Coskun, Tamer
Perfield, James W.
Bauer, Steven
Wade, Mark
Chouinard, Tara E.
Brozinick, Joseph T.
Adams, Andrew C.
Samms, Ricardo J.
author_sort Antonellis, Patrick J.
collection PubMed
description OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Administration of FGF19 to obese/diabetic mice lowers body weight, improves insulin sensitivity, and enhances glycemic control. The primary target organ of FGF19 is the liver, where it regulates bile acid homeostasis in response to nutrient absorption. In contrast, the broader pharmacologic actions of FGF19 are proposed to be driven, in part, by the recruitment of the thermogenic protein uncoupling protein 1 (UCP1) in white and brown adipose tissue. However, the precise contribution of UCP1-dependent thermogenesis to the therapeutic actions of FGF19 has not been critically evaluated. METHODS: Using WT and germline UCP1 knockout mice, the primary objective of the current investigation was to determine the in vivo pharmacology of FGF19, focusing on its thermogenic and anti-obesity activity. RESULTS: We report that FGF19 induced mRNA expression of UCP1 in adipose tissue and show that this effect is required for FGF19 to increase caloric expenditure. However, we demonstrate that neither UCP1 induction nor an elevation in caloric expenditure are necessary for FGF19 to induce weight loss in obese mice. In contrast, the anti-obesity action of FGF19 appeared to be associated with its known physiological role. In mice treated with FGF19, there was a significant reduction in the mRNA expression of genes associated with hepatic bile acid synthesis enzymes, lowered levels of hepatic bile acid species, and a significant increase in fecal energy content, all indicative of reduced lipid absorption in animals treated with FGF19. CONCLUSION: Taken together, we report that the anti-obesity effect of FGF19 occurs in the absence of UCP1. Our data suggest that the primary way in which exogenous FGF19 lowers body weight in mice may be through the inhibition of bile acid synthesis and subsequently a reduction of dietary lipid absorption.
format Online
Article
Text
id pubmed-6807368
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-68073682019-10-28 The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis Antonellis, Patrick J. Droz, Brian A. Cosgrove, Richard O'Farrell, Libbey S. Coskun, Tamer Perfield, James W. Bauer, Steven Wade, Mark Chouinard, Tara E. Brozinick, Joseph T. Adams, Andrew C. Samms, Ricardo J. Mol Metab Brief Communication OBJECTIVE: Fibroblast growth factor 19 (FGF19) is a postprandial hormone which plays diverse roles in the regulation of bile acid, glucose, and lipid metabolism. Administration of FGF19 to obese/diabetic mice lowers body weight, improves insulin sensitivity, and enhances glycemic control. The primary target organ of FGF19 is the liver, where it regulates bile acid homeostasis in response to nutrient absorption. In contrast, the broader pharmacologic actions of FGF19 are proposed to be driven, in part, by the recruitment of the thermogenic protein uncoupling protein 1 (UCP1) in white and brown adipose tissue. However, the precise contribution of UCP1-dependent thermogenesis to the therapeutic actions of FGF19 has not been critically evaluated. METHODS: Using WT and germline UCP1 knockout mice, the primary objective of the current investigation was to determine the in vivo pharmacology of FGF19, focusing on its thermogenic and anti-obesity activity. RESULTS: We report that FGF19 induced mRNA expression of UCP1 in adipose tissue and show that this effect is required for FGF19 to increase caloric expenditure. However, we demonstrate that neither UCP1 induction nor an elevation in caloric expenditure are necessary for FGF19 to induce weight loss in obese mice. In contrast, the anti-obesity action of FGF19 appeared to be associated with its known physiological role. In mice treated with FGF19, there was a significant reduction in the mRNA expression of genes associated with hepatic bile acid synthesis enzymes, lowered levels of hepatic bile acid species, and a significant increase in fecal energy content, all indicative of reduced lipid absorption in animals treated with FGF19. CONCLUSION: Taken together, we report that the anti-obesity effect of FGF19 occurs in the absence of UCP1. Our data suggest that the primary way in which exogenous FGF19 lowers body weight in mice may be through the inhibition of bile acid synthesis and subsequently a reduction of dietary lipid absorption. Elsevier 2019-09-29 /pmc/articles/PMC6807368/ /pubmed/31767164 http://dx.doi.org/10.1016/j.molmet.2019.09.006 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Communication
Antonellis, Patrick J.
Droz, Brian A.
Cosgrove, Richard
O'Farrell, Libbey S.
Coskun, Tamer
Perfield, James W.
Bauer, Steven
Wade, Mark
Chouinard, Tara E.
Brozinick, Joseph T.
Adams, Andrew C.
Samms, Ricardo J.
The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
title The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
title_full The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
title_fullStr The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
title_full_unstemmed The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
title_short The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
title_sort anti-obesity effect of fgf19 does not require ucp1-dependent thermogenesis
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6807368/
https://www.ncbi.nlm.nih.gov/pubmed/31767164
http://dx.doi.org/10.1016/j.molmet.2019.09.006
work_keys_str_mv AT antonellispatrickj theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT drozbriana theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT cosgroverichard theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT ofarrelllibbeys theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT coskuntamer theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT perfieldjamesw theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT bauersteven theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT wademark theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT chouinardtarae theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT brozinickjosepht theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT adamsandrewc theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT sammsricardoj theantiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT antonellispatrickj antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT drozbriana antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT cosgroverichard antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT ofarrelllibbeys antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT coskuntamer antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT perfieldjamesw antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT bauersteven antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT wademark antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT chouinardtarae antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT brozinickjosepht antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT adamsandrewc antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis
AT sammsricardoj antiobesityeffectoffgf19doesnotrequireucp1dependentthermogenesis